Radiofrequency ablation (RFA), as a minimally invasive treatment, is adopted for patients with early-stage hepatocellular carcinoma (HCC) who are not eligible for surgical resection or liver transplantation (1) (2) (3) . It is also used for treating recurrent HCC after hepatectomy, ablation, or liver transplantation (4, 5) . However, one of major drawbacks is the high rate of disease recurrence with an adverse effect on patient survival (6) .
Iodine [
131 I] metuximab injection (Licartin, Chengdu Huashen Biotechnology, Chengdu, China) is a radioimmunoconjugate generated by labeling metuximab directed against CD147 with iodine-131. CD147 is known as an extracellular matrix metalloproteinase inducer that was associated with hepatocarcinogenesis and tumor metastasis (7, 8) and correlated with HCC grading (9) . Combination of [ 131 I] metuximab with liver transplantation or TACE (transcatheter arterial chemoembolization) showed an improved clinical efficacy in HCC therapy (10) (11) (12) .
RFA causes cell damage by heat-induced coagulative necrosis and innate immunity activation. However, because of the limitations of heat dissipation and modest immune response, combining RFA with radioimmunotherapy probably has the potential to enhance outcome by directly targeted cell death (ie, hyperthermia, irradiation, and antibody) and indirectly adaptive immunity (13, 14) . We performed a randomized controlled trial (Chictr.org identifier: ChiCTR-TRC-10000837) to assess the efficacy and safety of [ The sample size was calculated using the historic cohort analysis of overall recurrence in this center. We needed 56 patients in each group (power of 90%, twosided statistical significance level of 5%, 1:1 allocation) to detect a 30% recurrence rate of difference between groups. We also estimated and added 10% of patients who might be lost to follow-up. On the basis of these calculations, we estimated that we needed to enroll at least 124 patients.
Patients were recruited at a single center according to the guidelines from the European Association for the Study of the Liver (15): two imaging techniques or one imaging with α-fetoprotein greater than 400 ng/mL (n = 80) or cytological/histological evidence (n = 47). The eligibility criteria are described in the Supplementary Materials (available online). The study was conducted with the approval of the institutional ethics board of Beijing Youan Hospital of Capital Medical University. Written informed consent was obtained from each patient.
RFA was performed with computed tomography (CT) guidance. A single ablation with a cool-tip RFA single or cluster electrodes or multiple overlapping ablations with a cluster electrode were performed for tumors less than 3.0 cm and 3.0 cm and larger, respectively. If the ablation zone completely covered the tumor and ablation margin without new and residual lesions, the treatment was considered a complete destruction, otherwise an additional session of RFA was given. For patients with multiple and larger size tumors, two rounds of RFA were performed to ablate all lesions within 14 days depending on the liver function, but were considered one session. No more than three applications of RFA were given in a treatment. The injection of [ 131 I] metuximab (27.75 MBq/kg) followed the last RFA within 30 days (median = 15 days; range = 3-29 days). Lugol's liquid was given starting three days before injection. A negative response to a subcutaneous metuximab injection was confirmed before the administration (16) .
The primary outcome was overall recurrence. The criteria for establishing tumor recurrence is described in the Supplementary Materials (available online). The patients were followed up with once
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Downloaded from https://academic.oup.com/jnci/article-abstract/106/9/dju239/913340 by guest on 06 January 2019 every three months for the first year and once every six months thereafter. Tumor measurements were performed by blinded reviews. Secondary outcomes included overall survival and safety. Randomization was conducted using a computer program to achieve a balance between the two groups with stratification according to BCLC stage (stage 0-A vs stage B), tumor number (single vs multiple), and tumor size (<3 cm vs ≥3 cm). The data analysis was performed when overall 50% of the patients experienced a tumor recurrence. Outcomes were assessed according to the intention-to-treat principle. Comparisons between two groups were performed using the Student's t test for continuous data and the chi-square test for categorical data. Adverse events were compared with the Fisher's exact test. The proportional hazard assumption was checked by graphical inspection of the linearity of the hazards over time and log-log plots and by plotting Schoenfeld residuals over time. Statistical analyses were performed with SPSS 16.0 software (Statistical Product and Service Solutions, Chicago, IL).
As no competing risk events were observed, 1-Kaplan-Meier estimator was chosen to estimate the cumulative probability of recurrence, and two groups were compared using a log-rank test and confirmed by Cox proportional hazards models, stratified by BCLC stage, tumor number, and tumor size. All statistical tests were two-sided. A P value of less than .05 was considered statistically significant.
From April 13, 2010 to July 18, 2013, 127 patients were analyzed with 62 patients assigned to the RFA-[ 131 I] metuximab group and 65 patients assigned to the RFA group (Figure 1 ). There were no statistically significant differences between the two study groups in demographic characteristics ( Table 1 ). The one-and two-year recurrence rates in the RFA-[ 131 I] metuximab group were 31.8% and 58.5%, whereas those in the RFA group were 56.3% and 70.9%, respectively. The median time to overall tumor recurrence was 17 months in the combination group and 10 months in the RFA group (HR = 0.60, 95% confidence interval [CI] = 0.38 to 0.96, P = .03) (Figure 2A ). Using the log-rank test stratified by the three variables, the RFA-[ * P value was calculated using the chi-square test (two-sided). AFP = α-fetoprotein; ALB = albumin; ALT = alanine transaminase; AST = aspartate amino transferase; BCLC = Barcelona Clinic Liver Cancer staging system; HBV = hepatitis B virus; HCV = hepatitis C virus; RFA = radiofrequency ablation; SD = standard deviation; TBIL = total bilirubin; TT3 = total triiodotyronine; TT4 = total tetraiodothyronine; TACE = transcatheter arterial chemoembolization; TSH = thyroid stimulating hormone. † P value was calculated using the Student's t test (two-sided). ‡ Patients might have received more than one type of therapy. metuximab treatment (n = 22) showed better overall survival than the RFA treatment (n = 21) (HR = 0.11, 95% CI = 0.01 to 1.10, P = .03) ( Figure 2D ). Adverse events were predominantly grades 1 or 2 in clinical and laboratory toxicities (Supplementary 
